CGIX News and Press, Cancer Genetics Inc. From 11/20/19

Cancer Genetics (NASDAQ: CGIX ): Q3 GAAP EPS of -$2.38. More news on: Cancer Genetics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

RUTHERFORD, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the third quarter ended September 30, 2019. RECENT S...

Gainers:  Karuna Therapeutics (NASDAQ: KRTX ) +282% More news on: Karuna Therapeutics, Inc., Hermitage Offshore Services Ltd., Eltek Ltd., Stocks on the move, Read more ...

Cancer Genetics ( CGIX -15.5% ) announced a 1-for-30 reverse stock split of its outstanding common stock, effective for trading purposes as of the commencement of trading on October 25, 2019. More news on: Cancer Genetics, Inc., Healthcare stocks news, Read more ...

RUTHERFORD, N.J, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding common stock. This will be effecti...

PARSIPPANY, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes the second tranche of the overall $27 ...

Cancer Genetics (NASDAQ: CGIX ): Q2 GAAP EPS of -$0.01. Revenue of $1.53M (+19.5% Y/Y) Press Release More news on: Cancer Genetics, Inc., Earnings news and commentary, Healthcare stocks news, ,

RUTHERFORD, N.J., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the second quarter ended June 30, 2019.    ...

Interpace Diagnostics (NASDAQ: IDXG ) has acquired Cancer Genetics' (NASDAQ: CGIX ) Biopharma Services business for ~$23.5M subject to adjustments. The business generated ~$15M in revenue in 2018. More news on: Interpace Diagnostics Group, Inc., Cancer Genetics, Inc., Healthcare stocks n...

Sale of BioPharma business to Interpace Diagnostics Group, Inc. Clinical services business acquired by siParadigm Diagnostic Informatics Significantly reduces its debt burden and will continue to operate its Discovery Business RUTHERFORD, N.J., July 15, 2019 (GLOBE NEWSWIRE) --...